Novo Nordisk (NYSE: NVO) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning of the coronavirus pandemic through the middle of last June, shares of NovoNordisk delivered more than a five-fold return.

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was over. It said the Danish pharmaceutical had sufficient supply of its semaglutide therapies to meet current and future,

Novo Nordisk's (NYSE: NVO) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance that easily beat the recovering S&P 500's (SNPINDEX: ^GSPC) 1.

U.S. stocks reversed early gains and fell around noon after a weak jobs report and concerns over stagflation. At noon in New York, the S&P 500 dipped 0.57%, while the Nasdaq 100 dropped 0.68%. The Dow Jones Industrial Average shed 0.

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame, as seen in the chart below.